A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

Por Gordon, Michael S., Mendelson, David S., Gross, Mitchell, Uttenreuther-Fischer, Martina, Ould-Kaci, Mahmoud, Zhao, Yihua, Stopfer, Peter, Agus, David B.
Publicado em 2012

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

Por Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann
Publicado no Cancer Chemother Pharmacol (2016)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Por Schnell, David, Buschke, Susanne, Fuchs, Holger, Gansser, Dietmar, Goeldner, Rainer-Georg, Uttenreuther-Fischer, Martina, Stopfer, Peter, Wind, Sven, Petersen-Sylla, Marc, Halabi, Atef, Koenen, Rüdiger
Publicado em 2014

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progre...

Por Gunzer, Katharina, Joly, Florence, Ferrero, Jean-Marc, Gligorov, Joseph, de Mont-Serrat, Helene, Uttenreuther-Fischer, Martina, Pelling, Katy, Wind, Sven, Bousquet, Guilhem, Misset, Jean-Louis
Publicado no Springerplus (2016)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

Por Marshall, John, Hwang, Jimmy, Eskens, Ferry A. L. M., Burger, Herman, Malik, Shakun, Uttenreuther-Fischer, Martina, Stopfer, Peter, Ould-Kaci, Mahmoud, Cohen, Roger B., Lewis, Nancy L
Publicado em 2012

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Por Lin, Nancy U., Winer, Eric P., Wheatley, Duncan, Carey, Lisa A., Houston, Stephen, Mendelson, David, Munster, Pamela, Frakes, Laurie, Kelly, Steve, Garcia, Agustin A., Cleator, Susan, Uttenreuther-Fischer, Martina, Jones, Hilary, Wind, Sven, Vinisko, Richard, Hickish, Tamas
Publicado em 2012

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine

Por Goh, Gerald, Schmid, Ramona, Guiver, Kelly, Arpornwirat, Wichit, Chitapanarux, Imjai, Ganju, Vinod, Im, Seock-Ah, Kim, Sung-Bae, Dechaphunkul, Arunee, Maneechavakajorn, Jedzada, Spector, Neil, Yau, Thomas, Afrit, Mehdi, Ahmed, Slim Ben, Johnston, Stephen R., Gibson, Neil, Uttenreuther-Fischer, Martina, Herrero, Javier, Swanton, Charles
Publicado no PLoS Med (2016)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Por Schuler, Martin, Awada, Ahmad, Harter, Philipp, Canon, Jean Luc, Possinger, Kurt, Schmidt, Marcus, De Grève, Jacques, Neven, Patrick, Dirix, Luc, Jonat, Walter, Beckmann, Matthias W., Schütte, Jochen, Fasching, Peter A., Gottschalk, Nina, Besse-Hammer, Tatiana, Fleischer, Frank, Wind, Sven, Uttenreuther-Fischer, Martina, Piccart, Martine, Harbeck, Nadia
Publicado em 2012